This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shoen, C. M.
Right arrow Articles by Cynamon, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shoen, C. M.
Right arrow Articles by Cynamon, M. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2000, p. 1458-1462, Vol. 44, No. 6
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Evaluation of Rifalazil in Long-Term Treatment Regimens for Tuberculosis in Mice

Carolyn M. Shoen,1 Sharon E. Chase,2 Michelle S. DeStefano,1 Tami S. Harpster,2 Alex J. Chmielewski,2 and Michael H. Cynamon1,2,*

State University of New York Upstate Medical University,1 and Department of Medicine, Veterans Affairs Medical Center,2 Syracuse, New York

Received 8 September 1999/Returned for modification 30 September 1999/Accepted 6 March 2000

Previous experiments with rifalazil (RLZ) (also known as KRM-1648) in combination with isoniazid (INH) demonstrated its potential for short-course treatment of Mycobacterium tuberculosis infection. In this study we investigated the minimum RLZ-INH treatment time required to eradicate M. tuberculosis in a murine model. RLZ-INH treatment for 6 weeks or longer led to a nonculturable state. Groups of mice treated in parallel were killed following an observation period to evaluate regrowth. RLZ-INH treatment for a minimum of 10 weeks was necessary to maintain a nonculturable state through the observation period. Pyrazinamide (PZA) was added to this regimen to determine whether the treatment duration could be further reduced. In this model, the addition of PZA did not shorten the duration of RLZ-INH treatment required to eradicate M. tuberculosis from mice. The addition of PZA reduced the number of mice in which regrowth occurred, although the reduction was not statistically significant.

* Corresponding author. Mailing address: VAMC, 800 Irving Ave., Syracuse, NY 13210. Phone: (315) 476-7461, ext. 3324. Fax: (315) 476-5348. E-mail: Michael.Cynamon{at}med.VA.gov.

Antimicrobial Agents and Chemotherapy, June 2000, p. 1458-1462, Vol. 44, No. 6
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Nikonenko, B. V., Protopopova, M., Samala, R., Einck, L., Nacy, C. A. (2007). Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs. Antimicrob. Agents Chemother. 51: 1563-1565 [Abstract] [Full Text]  
  • Nikonenko, B. V., Samala, R., Einck, L., Nacy, C. A. (2004). Rapid, Simple In Vivo Screen for New Drugs Active against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48: 4550-4555 [Abstract] [Full Text]  
  • Cynamon, M. H., Sklaney, M. (2003). Gatifloxacin and Ethionamide as the Foundation for Therapy of Tuberculosis. Antimicrob. Agents Chemother. 47: 2442-2444 [Abstract] [Full Text]  
  • Iseman, M.D. (2002). Tuberculosis therapy: past, present and future. Eur Respir J 20: 87S-94s [Abstract] [Full Text]  
  • Lenaerts, A. M., Chase, S. E., Cynamon, M. H. (2000). Evaluation of Rifalazil in a Combination Treatment Regimen as an Alternative to Isoniazid-Rifampin Therapy in a Mouse Tuberculosis Model. Antimicrob. Agents Chemother. 44: 3167-3168 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»